These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14734477)

  • 21. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy.
    Huang YY; Yu Z; Lin SF; Li S; Fong Y; Wong RJ
    J Clin Endocrinol Metab; 2007 May; 92(5):1965-70. PubMed ID: 17327376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
    Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
    Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy.
    Ino Y; Saeki Y; Fukuhara H; Todo T
    Clin Cancer Res; 2006 Jan; 12(2):643-52. PubMed ID: 16428511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antiviral efficacy of the murine alpha-1 interferon transgene against ocular herpes simplex virus type 1 requires the presence of CD4(+), alpha/beta T-cell receptor-positive T lymphocytes with the capacity to produce gamma interferon.
    Carr DJ; Noisakran S
    J Virol; 2002 Sep; 76(18):9398-406. PubMed ID: 12186922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
    Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
    J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
    Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
    Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice.
    Liu R; Varghese S; Rabkin SD
    Cancer Res; 2005 Feb; 65(4):1532-40. PubMed ID: 15735042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
    Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
    Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Herpes oncolytic therapy of salivary gland carcinomas.
    Reid V; Yu Z; Schuman T; Li S; Singh P; Fong Y; Wong RJ
    Int J Cancer; 2008 Jan; 122(1):202-8. PubMed ID: 17764117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of aggressive thyroid cancer with an oncolytic herpes virus.
    Yu Z; Eisenberg DP; Singh B; Shah JP; Fong Y; Wong RJ
    Int J Cancer; 2004 Nov; 112(3):525-32. PubMed ID: 15382081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PolySia-Specific Retargeting of Oncolytic Viruses Triggers Tumor-Specific Immune Responses and Facilitates Therapy of Disseminated Lung Cancer.
    Kloos A; Woller N; Gürlevik E; Ureche CI; Niemann J; Armbrecht N; Martin NT; Geffers R; Manns MP; Gerardy-Schahn R; Kühnel F
    Cancer Immunol Res; 2015 Jul; 3(7):751-63. PubMed ID: 25701327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic herpes simplex virus treatment of metastatic breast cancer.
    Wang J; Hu P; Zeng M; Rabkin SD; Liu R
    Int J Oncol; 2012 Mar; 40(3):757-63. PubMed ID: 22108767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining IL-10 and Oncolytic Adenovirus Demonstrates Enhanced Antitumor Efficacy Through CD8
    Chen D; Huang L; Zhou H; Zhang Y
    Front Immunol; 2021; 12():615089. PubMed ID: 33717103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
    Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
    Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic viral therapy for human ovarian cancer using a novel replication-competent herpes simplex virus type I mutant in a mouse model.
    Nawa A; Nozawa N; Goshima F; Nagasaka T; Kikkawa F; Niwa Y; Nakanishi T; Kuzuya K; Nishiyama Y
    Gynecol Oncol; 2003 Oct; 91(1):81-8. PubMed ID: 14529666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of intravenous versus intraperitoneal administration of oncolytic herpes simplex virus 1 for peritoneal carcinomatosis in mice.
    Kulu Y; Dorfman JD; Kuruppu D; Fuchs BC; Goodwin JM; Fujii T; Kuroda T; Lanuti M; Tanabe KK
    Cancer Gene Ther; 2009 Apr; 16(4):291-7. PubMed ID: 18989355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
    Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
    Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes.
    Carew JF; Kooby DA; Halterman MW; Kim SH; Federoff HJ; Fong Y
    Mol Ther; 2001 Sep; 4(3):250-6. PubMed ID: 11545616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα.
    Choi IK; Lee JS; Zhang SN; Park J; Sonn CH; Lee KM; Yun CO
    Gene Ther; 2011 Sep; 18(9):898-909. PubMed ID: 21451575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.